(Q47715661)

English

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

autosomal dominant polycystic kidney disease

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

autosomal dominant polycystic kidney

1 reference

based on heuristic

inferred from title

object named as

Antonio Pisani

6

0 references

Massimo Imbriaco

object named as

Massimo Imbriaco

8

0 references

object named as

Andrea Remuzzi

19

0 references

Giuseppe Remuzzi

object named as

Giuseppe Remuzzi

20

0 references

Piero Ruggenenti

21

object named as

Piero Ruggenenti

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

3

object named as

Annalisa Perna

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Antonio De Pascalis

object named as

Antonio De Pascalis

14

0 references

object named as

Anna Caroli

1

0 references

Norberto Perico

2

object named as

Norberto Perico

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

17

object named as

Nadia Rubis

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Silvia Prandini

18

object named as

Silvia Prandini

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

15

object named as

Flavio Gaspari

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Fabiola Carrara

16

object named as

Fabiola Carrara

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Erasmo Buongiorno

13

object named as

Erasmo Buongiorno

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Piergiorgio Messa

9

object named as

Piergiorgio Messa

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

11

object named as

Mauro Dugo

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Bianca Visciano

7

object named as

Bianca Visciano

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

author name string

Luca Antiga

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Paolo Brambilla

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Roberta Cerutti

10

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Luca Cancian

12

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

ALADIN study group

22

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

language of work or name

0 references

publication date

21 August 2013

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

382

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

1485-1495

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

9903

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Clinical practice. Autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatostatin limits rise in glomerular filtration rate after a protein meal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of recombinant human growth hormone (rhGH) on hemoglobin concentration in children with idiopathic growth hormone deficiency-related anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of long term octreotide on gall stone formation and gall bladder function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus in patients with autosomal dominant polycystic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961407-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)61407-5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23972263

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47715661&oldid=1744067998"